Slide 1: Q1 2025 Earnings Presentation
BRUKER CORPORATION (NASDAQ: BRKR) Q1 2025 Earnings Presentation May 7, 2025 Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Director, Investor Relations
Slide 2: Safe Harbor Statement
BRUKER CORP ORATI ON Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 193
Slide 3: Business Update
Q1 2025 Business Update 3
Slide 4: Q1 2025: Solid Revenue Growth; Organic Non-GAAP Operating Margin Expansion Offset by M&A Headwinds
Q1 2025: Solid Revenue Growth; Organic Non-GAAP Operating Margin Expansion more than Offset by Expected M&A Margin Headwinds Q1 2025 Performance; Year-over-Year Changes Q1 Financials Revenues [$M] ❖ Revenue increase of $79.7M, or +11.0% ▪ Constant-exchange rate (CER) growth: +12.5% 801.4 +11.0% 721.
Slide 5: Group CER Q1 2025 Revenue Performance YoY
GROUP OVERVIEW Group CER Q1 2025 Revenue Performance YoY Bruker BIOSPIN Group ▪ BIOSPIN CER revenue up mid teens% ▪ Strong contributions from preclinical imaging and lab automation ▪ Strong Aca/Gov revenues, including UHF NMR ▪ Strong growth in Europe and APAC ex-China ▪ Strength in industrial and f
Slide 6: Group CER Q1 2025 Revenue Performance YoY
GROUP OVERVIEW Group CER Q1 2025 Revenue Performance YoY Bruker NANO Group ▪ NANO CER revenue up high single digits% ▪ Growth aided by NanoString, not yet included in Q1-24 ▪ Softness in X-Ray and NanoAnalysis tools ▪ Strong growth in APAC ex-China, softness in Europe and China ▪ Strength in biophar
Slide 7: Recent Innovations: Advancing Spatial Biology with Best-in-Class Platforms
IN N OVATION EN G IN E Recent Innovations: Advancing Spatial Biology with Pioneering, Best-in-Class Platforms and Broadest Spatial Portfolio CellScape CosMx PowerOMX Software and EpicIF Whole Transcriptome Differentiated quantitative performance for continuum (WTX) Panel in protein expression; robus
Slide 8: April 2025 Majority Acquisition of RECIPE: Adding Therapeutic Drug Monitoring Diagnostic Assays
PROJECT ACCELERATE M&A April 2025 Majority Acquisition of RECIPE: Adding Therapeutic Drug Monitoring Diagnostic Assays ❖ RECIPE is a leading European provider of therapeutic drug monitoring (TDM), other IVDx kits for LC-MS, HPLC, and ICP-MS ❖ Based in Munich, Germany with >60 employees and over 40 y
Slide 9: Financial Update
Q1 2025 Financial Update 9
Slide 10: Q1 2025 Selected Non-GAAP Financial Measures
Q1 2025 YEAR-OVER-YEAR COMPARISON Q1 2025 Selected Non-GAAP Financial Measures1 [$ m, except EPS] Q1 2025 Q1 2024 Δ Comments (year-over-year) Total Revenues 801.4 721.7 11.0% ▪ Revenue growth of 11.0% Gross Profit 410.9 369.4 11.2% Margin (% of revenues) 51.3% 51.2% 10 bps ▪ BSI organic revenue grow
Slide 11: Q1 2025 Selected Cash Flow And Balance Sheet Measures
Q1 2025 YEAR-OVER-YEAR COMPARISON Q1 2025 Selected Cash Flow And Balance Sheet Measures [$M] Q1 2025 Q1 2024 Δ Comments (year-over-year) GAAP Net Income 16.8 52.0 (35.2) Depreciation & amortization 50.4 34.7 15.7 ▪ Free cash flow up +$38.6M, driven by: Changes in working capital1 14.8 (57.5) 72.3 ▪
Slide 12: FY 2025 Outlook
CEQ) So ea - FY 2025 Outlook = PA G
Slide 13: Updated FY 2025 Financial Outlook (as of May 7, 2025)
Updated FY 2025 Financial Outlook (as of May 7 , 2025) th Non-GAAP Assumptions & Estimates FY 2025 Guidance (year-over-year %s) ▪ Impact of policy changes and tariffs, before mitigation: Revenue $3.48B to $3.55B ▪ Revenue: gross headwind of ~$100M ▪ Operating profit: gross headwind of ~$90M Reported
Slide 14: Appendix
CEQ) So Appendix
Slide 15: Q1 2025 Summary of Reported Revenue Growth Components
APPENDIX Q1 2025 Summary of Reported Revenue Growth Components [$M] Q1 2025 Q1 2024 Revenue as of the prior comparable period 721.7 685.3 Acquisitions and divestures 69.2 26.3 Organic 20.9 11.1 Currency (10.4) (1.0) Revenue as of the current period 801.4 721.7 Revenue growth 11.0% 5.3% Organic reven
Slide 16: Q1 2025 Selected GAAP Results Year-over-Year
APPENDIX Q1 2025 Selected GAAP Results Year-over-Year [$M, except EPS] Q1 2025 Q1 2024 Δ Total Revenues 801.4 721.7 11.0% Gross Profit 391.2 352.8 10.9% Margin (% of revenue) 48.8% 48.9% SG&A (225.4) (195.3) 15.4% (% of revenues) 28.1% 27.1% R&D (97.1) (81.8) 18.7% (% of revenues) 12.1% 11.3% Operat
Slide 17: Q1 2025 Reconciliation of selected GAAP to Non-GAAP Financial Measures
APPENDIX Q1 2025 Reconciliation of selected GAAP to Non-GAAP Financial Measures Sum of items may not total due to rounding © 2025 2022 Bruker + -Bruker Q1 2025 Earnings Presentation | May 7, 2025 | 17
Slide 18: Q1 2024 Reconciliation of selected GAAP to Non-GAAP Financial Measures
APPENDIX Q1 2024 Reconciliation of selected GAAP to Non-GAAP Financial Measures Sum of items may not total due to rounding © 2025 2022 Bruker + -Bruker Q1 2025 Earnings Presentation | May 7, 2025 | 18
Slide 19: Q1 2025 Reconciliation of selected GAAP to Non-GAAP Financial Measures
APPENDIX Q1 2025 Reconciliation of selected GAAP to Non-GAAP Financial Measures Full Company Organic Revenue & CER Revenue Sum of items may not total due to rounding © 2025 2022 Bruker + -Bruker Q1 2025 Earnings Presentation | May 7, 2025 | 19
Slide 20: Q1 2025 Reconciliation of selected GAAP to Non-GAAP Financial Measures
APPENDIX Q1 2025 Reconciliation of selected GAAP to Non-GAAP Financial Measures Segment Organic Revenue & CER Revenue Sum of items may not total due to rounding © 2025 2022 Bruker + -Bruker Q1 2025 Earnings Presentation | May 7, 2025 | 20
Slide 21: Balance Sheet
APPENDIX Balance Sheet [$M] Mar 31, 2025 Dec 31, 2024 Total Assets 5,933.1 5,806.7 Working Capital* 1,409.7 1,395.5 Goodwill, Intangibles, Net & Other Long-Term Assets 3,132.6 3,084.2 [$M] Mar 31, 2025 Dec 31, 2024 Cash, Cash Equivalents & Short-term Investments 184.2 183.4 Financial Debt 2,116.7 2,
Slide 22: Q1 2025 BSI and BEST GAAP Performance Year-over-Year
APPENDIX Q1 2025 BSI and BEST GAAP Performance Year-over-Year [$M] Q1 2025 Q1 2024 Δ REVENUE Scientific Instruments (BSI) 744.5 651.1 14.3% Organic Revenue Growth (%) 5.1% 0.0% Energy & Supercon Technologies (BEST) 59.3 73.1 (18.9%) Corporate Eliminations (2.4) (2.5) Energy & Supercon Technologies (
Slide 23: ;
;